GlassScriptPhysician profile
Venugopal Depala
NPI 1699877480
$12,410.55
in general payments reported to CMS, 2019-2025
29 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,823 · 2020: $988 · 2023: $1,448 · 2024: $1,124 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,599.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,353.26 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $3,315.09 | 2019-2020 | |
| Tris Pharma INC | $759.84 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Otsuka America Pharmaceutical, INC. | $565.99 | 2019-2025 | Rexulti |
| Alkermes, INC. | $560.82 | 2023-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $362.39 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $359.79 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $300.29 | 2019-2024 | Spravato |
| Abbvie INC. | $278.95 | 2023-2025 | Vraylar |
| Lundbeck LLC | $276.34 | 2019-2024 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.39 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $185.05 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $155.28 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $120.15 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $102.84 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $94.76 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $61.54 | 2023-2024 | Ingrezza |
| Neos Therapeutics, LP | $61.44 | 2025 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $55.70 | 2019-2023 | Austedo Xr |
| Harmony Biosciences LLC | $40.76 | 2024 | |
| Vertical Pharmaceuticals, LLC | $37.31 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $34.38 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $22.14 | 2019 | |
| Almatica Pharma LLC | $17.40 | 2025 | Loreev Xr |
| Tonix Medicines, INC. | $15.88 | 2025 | Tonmya |
| Orexo US, INC. | $12.40 | 2019 | |
| Neuronetics, INC. | $11.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.59 | 2019 | |
| Janssen Scientific Affairs, LLC | $10.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venugopal Depala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.